Cyclo Therapeutics (CYTH) Institutional Ownership $1.15 +0.03 (+2.68%) (As of 07/26/2024 ET) Add Compare Share Share OwnershipStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends Institutional Ownership Changes (13F Filings) for Cyclo Therapeutics (NASDAQ:CYTH)CurrentInstitutional OwnershipPercentage68.55%Number ofInstitutional Buyers(last 12 months)2TotalInstitutional Inflows(last 12 months)$939.26KNumber ofInstitutional Sellers(last 12 months)0 Get CYTH Insider Trade Alerts Want to know when executives and insiders are buying or selling Cyclo Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address Skip Chart & View Institutional Buying and Selling Data CYTH Institutional Buying and Selling by Quarter Ad Paradigm PressMan who Predicted Trump 2016 Win: “Prepare for Election Meltdown”Former advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… A predicted Trump would win. You won’t believe what he’s predicting now.Click here to see it because it’s a SHOCKER… Cyclo Therapeutics Major Shareholders & Ownership History Export to ExcelReporting DateMajor Shareholder NameShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails2/15/2024Founders Fund V Management LLC480,708$764K80.8%N/A2.115% 2/15/2024Founders Fund VI Management LLC110,023$175K1.4%N/A0.484% 11/9/2021BlackRock Inc.13,134$88K0.0%+21.1%0.204% 8/16/2021State Street Corp44,700$457K0.0%N/A0.703% 8/13/2021Geode Capital Management LLC42,577$435K0.0%+133.2%0.670% 8/13/2021Vanguard Group Inc.151,540$1.55M0.0%+350.4%2.383% 5/12/2021Geode Capital Management LLC18,257$149K0.0%N/A0.287% 3/26/2021Susquehanna International Group LLP15,656$68K0.0%N/A0.249% 2/17/2021Jane Street Group LLC27,892$121K0.0%N/A1.641% 2/17/2021Worth Venture Partners LLC88,690$386K0.3%N/A5.217% 2/16/2021Armistice Capital LLC100,000$435K0.0%N/A5.882% (Data available from 1/1/2016 forward) CYTH Institutional Ownership - Frequently Asked Questions Who are the largest shareholders of CYTH shares? During the previous two years, the following institutional investors and hedge funds held shares of Cyclo Therapeutics shares: Founders Fund V Management LLC ($764K), Founders Fund VI Management LLC ($175K).Learn more on CYTH's institutional investors. What percentage of Cyclo Therapeutics stock is owned by institutional investors? 68.55% of Cyclo Therapeutics stock is owned by institutional investors. Learn more on CYTH's institutional investor holdings. Which institutional investors have been buying Cyclo Therapeutics stock? The following institutional investors have purchased Cyclo Therapeutics stock in the last 24 months: Founders Fund V Management LLC ($480.71K), and Founders Fund VI Management LLC ($110.02K). How much institutional buying is happening at Cyclo Therapeutics? Institutional investors have bought a total of 590,731 shares in the last 24 months. This purchase volume represents approximately $939.26K in transactions. Related Companies: ATHA Major Shareholders TVGN Major Shareholders OPT Major Shareholders VXRT Major Shareholders CLLS Major Shareholders CRDF Major Shareholders OMGA Major Shareholders ELUT Major Shareholders HLVX Major Shareholders DBVT Major Shareholders This page (NASDAQ:CYTH) was last updated on 7/27/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredFormer Hedge Fund Manager Issues Crash PredictionOur No. 1 stock for the rare "millionaire window" opening NOW According to Wall Street legend Whitney Tilso...Stansberry Research | SponsoredBrace Yourself: Experts calling for Bitcoin to hit $100kFor the past few months, Bitcoin has been trading flat… It's been stuck around the $60,000 to $72,000 range...Crypto 101 Media | SponsoredBreaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock (June 12) This $2 trillion D.C. shock i...Timothy Sykes | SponsoredGrab a pen and write down this ticker - here's whyA megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cyclo Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cyclo Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.